Side-by-side comparison of AI visibility scores, market position, and capabilities
Interactive coding education platform where students edit code inside tutorial videos; 120K+ monthly learners with YC backing competing with Codecademy for self-taught web development.
Scrimba is an interactive coding education platform that revolutionizes how programming is taught in video format — enabling students to edit and run code directly within tutorial videos, transforming passive watching into active coding practice through proprietary screencasting technology. Founded in 2017 in Oslo, Norway and backed by Y Combinator, Scrimba raised $400,000 and grew to 120,000+ monthly active learners with $1.9 million in revenue as of October 2024, serving the global population learning web development and programming.\n\nScrimba's core innovation is the "scrim" — an interactive screencast where the code editor is embedded within the video. When a tutorial plays, learners can pause at any point and edit the code directly in the player, test their changes, and continue — creating a hands-on learning experience where the video content and practice environment are the same thing. This eliminates the context switching between watching a video, opening a separate code editor, and typing out examples that makes traditional video tutorials less effective for kinesthetic learners.\n\nIn 2025, Scrimba competes in the online coding education market with freeCodeCamp (free self-paced learning), The Odin Project (free full-stack curriculum), Codecademy, Pluralsight, and Frontend Masters for self-taught developer education. Scrimba's interactive format is a genuine differentiator — the ability to immediately practice within the video context produces better learning retention than passive watching. The platform focuses primarily on front-end web development (JavaScript, React, CSS) which represents the highest-demand entry point for self-taught developers. The 2025 strategy focuses on expanding the course library, growing the community features (student projects, peer learning), and converting free learners to the Scrimba Pro subscription through the demonstrated value of the interactive format.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.